INCY - Incyte and CMS collaborate for povorcitinib in Mainland China Hong Kong Macau Taiwan and SEA
2024-04-01 09:35:23 ET
More on Incyte
- Incyte: A Potential GARP Superstar
- Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript
- Incyte Corporation 2023 Q4 - Results - Earnings Call Presentation
- FDA accepts Incyte application for graft-versus-host disease drug
- Incyte a new Buy at Jefferies on prospects beyond Jakafi